Gossamer Bio, Inc. announced the appointment of Joshua H. Bilenker, M.D., Russell J. Cox and Renée Galá to its Board of Directors. Ms. Galá will also serve as Chair of the Audit Committee. Dr. Bilenker, Mr. Cox and Ms. Galá will succeed Robert Nelsen and Richard Lim, who have served on the company’s Board of Directors since the company’s inception in January 2018. Gossamer also announced that Hillhouse Capital has appointed Dr. Vincent Xiang to replace Michael Yi as its director appointee. Dr. Joshua H. Bilenker, founder of Loxo Oncology, Inc., has served as Loxo’s President and Chief Executive Officer since July 2013. Dr. Bilenker joined Aisling Capital LLC, an investment firm, in April 2006 and has served as an Operating Partner since November 2013. Russell J. Cox has served as Chief Executive Officer at Vital Therapies, Inc. since January 2018. Prior to joining Vital, Mr. Cox served as the Executive Vice President and Chief Operating Officer, of Jazz Pharmaceuticals plc, with responsibility for global commercial activities, R&D, manufacturing/technical operations, new product planning and global molecule leadership. Renée Galá brings more than 20 years of finance, corporate strategy, and leadership experience. Effective January 3, 2019, she will become Chief Financial Officer at GRAIL, Inc., a healthcare company focused on the early detection of cancer. Currently, Ms. Galá is Senior Vice President and Chief Financial Officer at Theravance Biopharma following the company’s spinout from Theravance, Inc. Ms. Galá joined Theravance (now Innoviva, Inc.) and held various roles in the finance organization before leading the company’s spin-out transaction. Dr. Vincent Xiang is a Managing Director at Hillhouse Capital, responsible for its global bio venture investments. Previously, he was a Partner at 6 Dimensions Capital and was Managing Director and Head of International Investments & Business Development at Humanwell Healthcare Group. Prior to that, he worked as Managing Director of Burrill Life Science Venture Capital Fund, and Portfolio Manager/Analyst at Franklin Templeton, investing in global life science companies across all development stages.
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
GOSSAMER BIO, INC. 
